Zevra has sold its US Food and Drug Administration (FDA) priority review voucher (PRV) for $150m to an undisclosed party.

Zevra Therapeutics has inked a deal to sell its Food and Drug Administration priority-review voucher to an undisclosed buyer for gross proceeds of $150 million.

The last time I wrote about Precigen (NASDAQ:PGEN) it was with respect to a Seeking Alpha article entitled "Precigen: RRP ...

As we observe Rare Disease Day today, let us take a look at seven drugs poised to be approved to address rare diseases in ...

ACAD reports mixed fourth-quarter results as earnings missed estimates while revenues beat the same, driven by year-over-year growth in Nuplazid and Daybue sales.

Amit Shah said it should be the priority of Delhi Police to eliminate interstate gangs in Delhi with a ruthless approach ...

Want to earn twice as many tiles toward TrueBlue elite status with JetBlue? If you’re planning a cruise, listen up.

New Delhi: Union Home Minister Amit Shah on Friday spoke to Uttarakhand Chief Minister Pushkar Singh Dhami and took stock of ...

Shah's directive came during a high-level security review meeting in Delhi. The meeting was also attended by the ...

Trump’s border crackdown faces hurdles as immigration judges are terminated. Scripps News spoke with one of those terminated ...

From the top spy agency's biggest concern to two senators butting heads, here are some of the key moments from Senate ...

The Harborside's financial collapse underscores the challenges continuing care retirement communities face and the financial ...